Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer

<p>Proteins identified in RNA pulldown and mass spectrometry analysis with FZR1[m6A] or FZR1[A].</p>

Tallennettuna:

Bibliografiset tiedot
Päätekijä:	Jiachun Su (16990970) (author)
Muut tekijät:	Rui Li (16990973) (author), Ziming Chen (16990976) (author), Shaoqiu Liu (16990979) (author), Hongzhe Zhao (16990982) (author), Shuang Deng (16990985) (author), Lingxing Zeng (16990988) (author), Zilan Xu (16990991) (author), Sihan Zhao (16990994) (author), Yifan Zhou (16990997) (author), Mei Li (16991000) (author), Xiaowei He (16991003) (author), Ji Liu (16991006) (author), Chunling Xue (16991009) (author), Ruihong Bai (16991012) (author), Lisha Zhuang (16991015) (author), Quanbo Zhou (16991018) (author), Shaoping Zhang (16991021) (author), Rufu Chen (16991024) (author), Xudong Huang (16991027) (author), Dongxin Lin (16991030) (author), Jian Zheng (11732682) (author), Jialiang Zhang (16991033) (author)
Julkaistu:	2025
Aiheet:	Cancer Cancer Risk Factors Molecular and Cellular Biology Therapeutic Research and Development Chemotherapy Drug Resistance Regulation of gene expression in drug resistance Epigenetics Gastrointestinal Cancers Pancreatic cancer
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Tekijä: Dahihm Kim (16546203)
Julkaistu: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Tekijä: Dahihm Kim (16546203)
Julkaistu: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Tekijä: Dahihm Kim (16546203)
Julkaistu: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Tekijä: Dahihm Kim (16546203)
Julkaistu: (2025)

Figure S5 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Tekijä: Dahihm Kim (16546203)
Julkaistu: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Tekijä: Dahihm Kim (16546203)
Julkaistu: (2025)

Table S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Tekijä: Dahihm Kim (16546203)
Julkaistu: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Tekijä: Chong Kin Liam (15331321)
Julkaistu: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Tekijä: Chong Kin Liam (15331321)
Julkaistu: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Tekijä: Chong Kin Liam (15331321)
Julkaistu: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Tekijä: Chong Kin Liam (15331321)
Julkaistu: (2025)

Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
Tekijä: Gregory L. Beatty (15087193)
Julkaistu: (2025)

Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
Tekijä: Gregory L. Beatty (15087193)
Julkaistu: (2025)

Supplementary Table from CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization
Tekijä: Xiaohong Hong (22681698)
Julkaistu: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Tekijä: Sanna Pikkusaari (15055802)
Julkaistu: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Tekijä: Sanna Pikkusaari (15055802)
Julkaistu: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Tekijä: Yufang Bao (15386826)
Julkaistu: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Tekijä: Yufang Bao (15386826)
Julkaistu: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Tekijä: Yufang Bao (15386826)
Julkaistu: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Tekijä: Yufang Bao (15386826)
Julkaistu: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Tekijä: Yufang Bao (15386826)
Julkaistu: (2025)

Supplementary Table 1 from <i>N<sup>6</sup></i>-Methyladenosine Promotes Translation of VEGFA to Accelerate Angiogenesis in Lung Cancer
Tekijä: Haisheng Zhang (16436982)
Julkaistu: (2025)

Source Data from Ablation of p57<sup>+</sup> Quiescent Cancer Stem Cells Suppresses Recurrence after Chemotherapy of Intestinal Tumors
Tekijä: Takeru Oka (15386810)
Julkaistu: (2025)

Supplementary Table S1 from Ablation of p57<sup>+</sup> Quiescent Cancer Stem Cells Suppresses Recurrence after Chemotherapy of Intestinal Tumors
Tekijä: Takeru Oka (15386810)
Julkaistu: (2025)

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Tekijä: Seung Yeon Oh (15051017)
Julkaistu: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Tekijä: Seung Yeon Oh (15051017)
Julkaistu: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Tekijä: Seung Yeon Oh (15051017)
Julkaistu: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Tekijä: Seung Yeon Oh (15051017)
Julkaistu: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Tekijä: Seung Yeon Oh (15051017)
Julkaistu: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Tekijä: Seung Yeon Oh (15051017)
Julkaistu: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Tekijä: Seung Yeon Oh (15051017)
Julkaistu: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Tekijä: Seung Yeon Oh (15051017)
Julkaistu: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Tekijä: Seung Yeon Oh (15051017)
Julkaistu: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Tekijä: Seung Yeon Oh (15051017)
Julkaistu: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Tekijä: Seung Yeon Oh (15051017)
Julkaistu: (2025)

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Tekijä: Seung Yeon Oh (15051017)
Julkaistu: (2025)

Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Tekijä: Nicole A. Traphagen (16677391)
Julkaistu: (2025)

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Tekijä: Nicole A. Traphagen (16677391)
Julkaistu: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Tekijä: Alex C.H. Liu (14961921)
Julkaistu: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Tekijä: Alex C.H. Liu (14961921)
Julkaistu: (2025)

Cannot write session to /tmp/vufind_sessions/sess_mf0d4albc9i7num68hau97hrn5